Study of Gattex (NPS Pharma) shows treatment offers relief in Short-Bowel Syndrome

Gattex/Revestive (teduglutide), from NPS Pharma, offers significant relief for patients with Short-Bowel Syndrome intestinal failure who are reliant on intravenous nutrition. A year-long trial to determine the safety, tolerability and clinical efficacy of teduglutide showed that after 52 weeks, 68% of patients on just a low dose of teduglutide experienced lessened parenteral nutrition dependency and there was a greater than 20% reduction in IV-fluid requirements. The study also documented multiple patients who received complete independence from parenteral nutrition.

These findings instill hope that Short-Bowel Syndrome patients can achieve a significantly enhanced quality of life, free of sleep disturbances and limited social activities. Data was reported in Clinical Gastroenterology and Hepatology: "Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure" Stephen J.D. O'Keefe et al. Clinical Gastroenterology and Hepatology Vol. 11, Issue 7, Pages 815-823.e3